Literature DB >> 12499228

In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs.

Luis Alcalá1, María Jesús Ruiz-Serrano, Cristina Pérez-Fernández Turégano, Darío García De Viedma, Marisol Díaz-Infantes, Mercedes Marín-Arriaza, Emilio Bouza.   

Abstract

We evaluated 117 isolates of Mycobacterium tuberculosis for susceptibility to linezolid by the proportion and E-test methods. Linezolid showed high in vitro activity, with all the strains inhibited by <or=1 microg of the drug per ml. E-test MICs were at least 4 dilutions lower than their equivalents by the standard proportion method.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12499228      PMCID： PMC148996          DOI： 10.1128/AAC.47.1.416-417.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  [Multiresistant tuberculosis caused by Mycobacterium bovis and human immunodeficiency virus infection. Are there new therapeutic possibilities?].

Authors:  M E Valencia; V Moreno; F Laguna; J M González-Lahoz
Journal:  Enferm Infecc Microbiol Clin       Date:  2001-01       Impact factor: 1.731

2.  Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model.

Authors:  M H Cynamon; S P Klemens; C A Sharpe; S Chase
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates.

Authors:  E Cercenado; F García-Garrote; E Bouza
Journal:  J Antimicrob Chemother       Date:  2001-01       Impact factor: 5.790

Review 4.  Antituberculosis drugs and new drug development.

Authors:  S Agrawal; N S Thomas; A B Dhanikula; C L Kaul; R Panchagnula
Journal:  Curr Opin Pulm Med       Date:  2001-05       Impact factor: 3.155

5.  Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions.

Authors:  D L Shinabarger; K R Marotti; R W Murray; A H Lin; E P Melchior; S M Swaney; D S Dunyak; W F Demyan; J M Buysse
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

6.  Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project.

Authors:  C Dye; S Scheele; P Dolin; V Pathania; M C Raviglione
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

7.  In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.

Authors:  G E Zurenko; B H Yagi; R D Schaadt; J W Allison; J O Kilburn; S E Glickman; D K Hutchinson; M R Barbachyn; S J Brickner
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

8.  In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones.

Authors:  R N Jones; D M Johnson; M E Erwin
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191
  8 in total
  38 in total

1.  Clarithromycin significantly increases linezolid serum concentrations.

Authors:  Mathieu S Bolhuis; Richard van Altena; Donald R A Uges; Tjip S van der Werf; Jos G W Kosterink; Jan-Willem C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2010-09-13       Impact factor: 5.191

2.  Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis.

Authors:  Robert S Wallis; Wesley Jakubiec; Vikas Kumar; Gabriella Bedarida; Annette Silvia; Darcy Paige; Tong Zhu; Mark Mitton-Fry; Lynn Ladutko; Sheldon Campbell; Paul F Miller
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

3.  Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480.

Authors:  J W C Alffenaar; T van der Laan; S Simons; T S van der Werf; P J van de Kasteele; H de Neeling; D van Soolingen
Journal:  Antimicrob Agents Chemother       Date:  2011-01-03       Impact factor: 5.191

4.  In vitro susceptibility of Mycobacterium tuberculosis clinical isolates to garenoxacin and DA-7867.

Authors:  Lucio Vera-Cabrera; Jorge Castro-Garza; Adrian Rendon; Jorge Ocampo-Candiani; Oliverio Welsh; Sung Hak Choi; Kym Blackwood; Carmen Molina-Torres
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

5.  In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.

Authors:  Baohong Ji; Sébastien Lefrançois; Jerome Robert; Aurélie Chauffour; Chantal Truffot; Vincent Jarlier
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

6.  In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years.

Authors:  Tsi-Shu Huang; Yung-Ching Liu; Cheng-Len Sy; Yao-Shen Chen; Hui-Zin Tu; Bao-Chen Chen
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

7.  Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis.

Authors:  Bryan McGee; Reynaldo Dietze; David Jamil Hadad; Lucilia Pereira Dutra Molino; Ethel Leonor Noia Maciel; W Henry Boom; Moises Palaci; John L Johnson; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

8.  In Vitro Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China.

Authors:  Yu Pang; Zhaojing Zong; Fengmin Huo; Wei Jing; Yifeng Ma; Lingling Dong; Yunxu Li; Liping Zhao; Yuhong Fu; Hairong Huang
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

9.  Population Pharmacokinetics of AZD-5847 in Adults with Pulmonary Tuberculosis.

Authors:  Abdullah Alsultan; Jennifer J Furin; Jeannine Du Bois; Elana van Brakel; Phalkun Chheng; Amour Venter; Bonnie Thiel; Sara A Debanne; W Henry Boom; Andreas H Diacon; John L Johnson; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

10.  Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model.

Authors:  K N Williams; C K Stover; T Zhu; R Tasneen; S Tyagi; J H Grosset; E Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.